Bli medlem
Bli medlem

Du är här



Karo Bio's Annual Report 2013 has been published and is available on
the company's website

For further information, please contact:
Henrik Palm, CFO, mobile phone +46 70-540 40 14 or e-mail

About Karo Bio
Karo Bio is a research and development company focused on innovative
drugs for important medical needs. The world-leading knowledge of
nuclear receptors as target proteins for the development of
pharmaceuticals and their related mechanisms of action, are utilized
for developing novel, more effective and safer pharmaceuticals. Karo
Bio is active in preclinical development focused on the areas of
neuropsychiatry, inflammation, autoimmune diseases and cancer. Karo
Bio is based in Huddinge, Sweden. The company has around 39 employees
and is listed on NASDAQ OMX Stockholm.

This press release is also available online at and


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.